Végsö G, Toronyi E, Hajdu M, Piros L, Görög D, Deák P A, Doros A, Péter A, Langer R M
Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary.
Transplant Proc. 2011 May;43(4):1261-3. doi: 10.1016/j.transproceed.2011.03.068.
The frequency of malignant tumors as a cause of death is increasing among kidney transplant patients. The aim of our study was to characterize kidney tumors occurring in the native kidneys of renal transplanted patients, and to determine their impact on recipient survival.
We retrospectively analyzed the 43/3003 (1.43%) renal cell carcinomas (RCC) in the native kidneys of patients transplanted between 1973 and 2010.
During this period we diagnosed 293 posttransplant tumors, 14.6% of which were RCC. The male/female ratio was 2.1:1. The mean age of recipients at the time of tumor detection was 52.4 ± 12.1 years. The mean time from transplantation to diagnosis was 72.4 ± 61.6 months. RCC occurred on both sides in similar numbers. Tumors were multifocal in 8 cases. According to TNM staging, RCC was stage I in 38 cases. The histologic type was clear cell (n=27), papillary (n=13), chromophobe (n=2) or sarcomatoid (n=1). Radical nephrectomy was performed in 41 cases. Immunosuppressive management was converted to proliferation signal inhibitors in 27 patients (sirolimus n=19 or everolimus n=8). Fifteeen patients died at a mean survival time of 38.9 ± 62.4 months with 28 patients still alive at a mean follow-up 43.8 ± 35.6 months. Cumulative survival according to the Kaplan-Meier method was 79.2% at 1 year, 66.1% at 5 years, and 59.0% at 10 years. The patient survival rate was better among papillary than clear cell RCC (P=.038).
RCC was the second most frequent tumor among kidney transplanted patients at our center. The diagnosis established at an early stage in the majority of cases, leading to favorable patient survivals. A regular yearly abdominal ultrasound screening is suggested for early tumor diagnosis.
在肾移植患者中,恶性肿瘤作为死亡原因的发生率正在上升。我们研究的目的是描述肾移植患者自体肾中发生的肾肿瘤特征,并确定它们对受者生存的影响。
我们回顾性分析了1973年至2010年间接受移植患者自体肾中43例(占3003例的1.43%)肾细胞癌(RCC)。
在此期间,我们诊断出293例移植后肿瘤,其中14.6%为RCC。男女比例为2.1:1。肿瘤检测时受者的平均年龄为52.4±12.1岁。从移植到诊断的平均时间为72.4±61.6个月。双侧发生RCC的数量相似。8例肿瘤为多灶性。根据TNM分期,38例RCC为I期。组织学类型为透明细胞型(n=27)、乳头状型(n=13)、嫌色细胞型(n=2)或肉瘤样型(n=1)。41例患者接受了根治性肾切除术。27例患者的免疫抑制治疗转换为增殖信号抑制剂(西罗莫司n=19或依维莫司n=8)。15例患者死亡,平均生存时间为38.9±62.4个月,28例患者仍存活,平均随访时间为43.8±35.6个月。根据Kaplan-Meier方法,1年时的累积生存率为79.2%,5年时为66.1%,10年时为59.0%。乳头状RCC患者的生存率优于透明细胞RCC(P=0.038)。
RCC是我们中心肾移植患者中第二常见的肿瘤。大多数病例在早期确诊,患者生存率良好。建议每年定期进行腹部超声筛查以早期诊断肿瘤。